AASLD

Late-breaking abstract selected by AASLD as one of the “Best of the Liver Meeting” for 2022 Phase 2 for PXL065 in NASH achieved the primary efficacy endpoint for liver fat content reduction for all doses and showed strong improvement…

Data demonstrating nanomolar potency of core inhibitor ABI-4334 to disrupt the hepatitis B virus (HBV) life cycle at multiple points supports advancement into clinical studies First data presented on preclinical characterization of…

– Data from multiple ongoing trials evaluating Vir’s two novel HBV therapies continue to demonstrate substantial reductions in hepatitis B surface antigen (HBsAg) with no new safety signals – – Preliminary data to-date show that 30.8%…